The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

September 23, 2021

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Unresectable Colorectal Cancer
Interventions
DRUG

ONO-7913

Specified dose on specified days

DRUG

ONO-4538

Specified dose on specified days

DRUG

Fluorouracil

Specified dose on specified days

DRUG

Oxaliplatin

Specified dose on specified days

DRUG

Levofolinate

Specified dose on specified days

DRUG

Bevacizumab

Specified dose on specified days

DRUG

Cetuximab

Specified dose on specified days

Trial Locations (17)

Unknown

Fujita Health University Hospital, Toyoake

National Cancer Center Hospital East, Kashiwa

Hokkaido University Hospital, Sapporo

Kobe City Medical Center General Hospital, Kobe

St. Marianna University Hospital, Kawasaki

Kanagawa Cancer Center, Yokohama

Kurashiki Central Hospital, Kurashiki

Kansai Medical University Hospital, Hirakata

Osaka Medical and Pharmaceutical University Hospital, Takatsuki

Saitama Medical University International Medical Center, Hidaka

Saitama Cancer Center, Shinden

Cancer Institute Hospital of JFCR, Koto-Ku

National Cancer Center Hospital, Chūōku

Chiba Cancer Center, Chiba

National Hospital Organization Osaka National Hospital, Osaka

Osaka General Medical Center, Osaka

Osaka International Cancer Institute, Osaka

Sponsors
All Listed Sponsors
lead

Ono Pharmaceutical Co. Ltd

INDUSTRY